MX2021010553A - Profarmacos de abiraterona. - Google Patents

Profarmacos de abiraterona.

Info

Publication number
MX2021010553A
MX2021010553A MX2021010553A MX2021010553A MX2021010553A MX 2021010553 A MX2021010553 A MX 2021010553A MX 2021010553 A MX2021010553 A MX 2021010553A MX 2021010553 A MX2021010553 A MX 2021010553A MX 2021010553 A MX2021010553 A MX 2021010553A
Authority
MX
Mexico
Prior art keywords
abiraterone
prodrugs
syndrome due
excess
hypercortisolemia
Prior art date
Application number
MX2021010553A
Other languages
English (en)
Spanish (es)
Inventor
William R Moore
Matthew J Sharp
Original Assignee
Propella Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Propella Therapeutics Inc filed Critical Propella Therapeutics Inc
Publication of MX2021010553A publication Critical patent/MX2021010553A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2021010553A 2019-03-06 2020-03-04 Profarmacos de abiraterona. MX2021010553A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814568P 2019-03-06 2019-03-06
US201962849259P 2019-05-17 2019-05-17
PCT/US2020/020915 WO2020180942A1 (en) 2019-03-06 2020-03-04 Abiraterone prodrugs

Publications (1)

Publication Number Publication Date
MX2021010553A true MX2021010553A (es) 2021-12-15

Family

ID=70190090

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010553A MX2021010553A (es) 2019-03-06 2020-03-04 Profarmacos de abiraterona.

Country Status (15)

Country Link
US (4) US10792292B2 (cg-RX-API-DMAC7.html)
EP (2) EP4286006A3 (cg-RX-API-DMAC7.html)
JP (1) JP7644713B2 (cg-RX-API-DMAC7.html)
KR (1) KR102879575B1 (cg-RX-API-DMAC7.html)
CN (3) CN114026106B (cg-RX-API-DMAC7.html)
AU (1) AU2020232706B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021017377A2 (cg-RX-API-DMAC7.html)
CA (1) CA3131034A1 (cg-RX-API-DMAC7.html)
DK (1) DK3935068T3 (cg-RX-API-DMAC7.html)
ES (1) ES2964818T3 (cg-RX-API-DMAC7.html)
IL (1) IL286048B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021010553A (cg-RX-API-DMAC7.html)
PL (1) PL3935068T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020180942A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107278B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114026106B (zh) 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药
US12347562B2 (en) * 2019-12-26 2025-07-01 Cerner Innovation, Inc. Decision support application for PCOS
AU2021338271A1 (en) * 2020-09-02 2023-03-30 Astellas Us Llc Abiraterone prodrugs
CN113929727A (zh) * 2020-09-28 2022-01-14 南京易腾药物研究院有限公司 阿比特龙酯类衍生物及其制备方法和应用
CN117120034A (zh) * 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
CN113061154B (zh) * 2021-03-25 2022-07-08 天津海润家和创新医药研究有限责任公司 新型注射用阿比特龙衍生物的制备方法和用途
CN113527401A (zh) * 2021-08-26 2021-10-22 雷昊言 一种阿比特龙前体化合物及其制备方法和应用
WO2023038933A1 (en) * 2021-09-08 2023-03-16 Propella Therapeutics, Inc. Oral abiraterone formulations
CN119136813A (zh) * 2022-03-01 2024-12-13 普洛拉治疗公司 阿比特龙前药
WO2024107928A1 (en) * 2022-11-16 2024-05-23 Propella Therapeutics, Inc. Abiraterone decanoate composition and use in therapy
CN116046950A (zh) * 2023-01-18 2023-05-02 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) 一种检测醋酸阿比特龙中5种杂质的方法
LU506495B1 (en) * 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS
WO2026130540A1 (zh) * 2024-12-20 2026-06-25 长春金赛药业有限责任公司 一种阿比特龙衍生物、药物组合物及其制备方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
WO2003075958A1 (fr) 2002-03-11 2003-09-18 Takeda Chemical Industries, Ltd. Medicaments permettant de traiter une maladie dependant d'une hormone sexuelle
JP2004002321A (ja) * 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
TW200404552A (en) 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
CN102772358A (zh) 2005-06-16 2012-11-14 美瑞德生物工程公司 药物组合物及其用途
HRP20130961T1 (hr) 2006-08-25 2013-11-22 Janssen Oncology, Inc. Kombinacije za tretman raka
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20090124587A1 (en) 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
GB2479693B (en) 2009-02-05 2014-04-09 Tokai Pharmaceuticals Inc Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
EP2393827B1 (en) * 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2011066582A1 (en) 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
WO2011083830A1 (ja) 2010-01-06 2011-07-14 学校法人関西文理総合学園 新規抗がん剤およびそのスクリーニング方法
BR112013017635A2 (pt) 2010-12-16 2016-10-11 Biomarin Pharm Inc inibidores de cyp11b, cyp17 e/ou cyp21
DE102011083725A1 (de) 2011-09-29 2013-04-04 Bayer Pharma AG Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN104066744B (zh) 2011-10-10 2017-03-22 扎克系统公司 用于制备17‑取代的甾体的方法
MX367640B (es) 2011-11-30 2019-08-29 Astrazeneca Ab Tratamiento combinado del cáncer.
AU2012358219A1 (en) 2011-12-22 2014-07-10 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using P13K/mTOR inhibitors
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
WO2013159225A1 (en) 2012-04-23 2013-10-31 Alphora Research Inc. Process for preparation of 17-substituted steroids
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014016830A1 (en) 2012-07-25 2014-01-30 Mapi Pharma Ltd. Process and intermediates for the preparation of abiraterone acetate
US20140011992A1 (en) 2012-12-20 2014-01-09 Crystal Pharma, S.A.U. Synthesis of abiraterone and related compounds
EP2945628B1 (en) 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
CA2898573A1 (en) 2013-01-18 2014-07-24 Cortendo Ab (Publ) Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
TWI686212B (zh) 2013-03-15 2020-03-01 阿聯商太陽法瑪全球有限公司 醋酸阿比特龍配方
EP3738594A1 (en) 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Targeted therapeutics having an hsp90 ligand as binding moiety
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
MX2016004267A (es) 2013-10-01 2016-07-08 Novartis Ag Combinacion.
JP6576942B6 (ja) 2014-03-03 2019-11-27 マドリガル ファーマシューティカルズ インコーポレイテッド 標的治療薬
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
CN104017045B (zh) * 2014-06-23 2016-01-13 广州艾格生物科技有限公司 甾体cyp17抑制剂的新型药物前体及其应用、制备方法
US9937259B2 (en) 2014-06-27 2018-04-10 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivatives and non-covalent complexes with albumin
WO2016044701A1 (en) 2014-09-18 2016-03-24 Iceutica Inc. Abiraterone acetate formulation and methods of use
CN104356191A (zh) 2014-09-29 2015-02-18 上海延安药业(湖北)有限公司 阿比特龙单琥珀酸酯及其制备方法
CN106061990B (zh) 2014-11-28 2019-09-10 四川海思科制药有限公司 一种阿比特龙衍生物及其制备方法和医药用途
CN104447394B (zh) * 2014-12-17 2017-01-18 成都傲飞生物化学品有限责任公司 一种乌苯美司的新型合成工艺
CN104710499A (zh) 2015-02-15 2015-06-17 重庆医药工业研究院有限责任公司 一种丙酸阿比特龙的晶型及其制备方法
CN108112235A (zh) 2015-03-06 2018-06-01 克利夫兰临床基金会 改变类固醇代谢以用于治疗类固醇依赖性疾病
ES2954596T3 (es) * 2015-12-23 2023-11-23 Univ British Columbia Profármacos unidos a lípidos
JP6842474B2 (ja) 2016-02-02 2021-03-17 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Shenzhen TargetRx,Inc. ステロイド系化合物、当該化合物を含む組成物及びその使用
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
US10717762B2 (en) 2016-10-11 2020-07-21 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivative and formulations thereof
CN106977577A (zh) 2017-04-21 2017-07-25 湖南师范大学 两类阿比特龙衍生物的合成
JP2022523704A (ja) 2019-01-25 2022-04-26 シェンチェン・ファーマシン・カンパニー・リミテッド 医薬組成物
CN114026106B (zh) 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药
CN113825514A (zh) 2019-03-18 2021-12-21 分散技术有限责任公司 阿比特龙-环状寡聚体药物制剂及其形成和施用方法
AU2021338271A1 (en) 2020-09-02 2023-03-30 Astellas Us Llc Abiraterone prodrugs
CN113929727A (zh) 2020-09-28 2022-01-14 南京易腾药物研究院有限公司 阿比特龙酯类衍生物及其制备方法和应用
CN117120034A (zh) 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
WO2023038933A1 (en) 2021-09-08 2023-03-16 Propella Therapeutics, Inc. Oral abiraterone formulations

Also Published As

Publication number Publication date
DK3935068T3 (da) 2023-12-04
IL286048B2 (en) 2025-03-01
KR20210136072A (ko) 2021-11-16
CN114026106A (zh) 2022-02-08
WO2020180942A1 (en) 2020-09-10
PL3935068T3 (pl) 2024-02-26
EP3935068A1 (en) 2022-01-12
US20250099489A1 (en) 2025-03-27
EP3935068B1 (en) 2023-09-06
US20200368255A1 (en) 2020-11-26
CA3131034A1 (en) 2020-09-10
ZA202107278B (en) 2023-06-28
AU2020232706B2 (en) 2025-10-02
CN120531742A (zh) 2025-08-26
US20200281945A1 (en) 2020-09-10
EP4286006A3 (en) 2024-03-20
AU2020232706A1 (en) 2021-09-16
JP7644713B2 (ja) 2025-03-12
BR112021017377A2 (pt) 2021-11-16
ES2964818T3 (es) 2024-04-09
US12138273B2 (en) 2024-11-12
EP4286006A2 (en) 2023-12-06
IL286048A (en) 2021-10-31
US10792292B2 (en) 2020-10-06
JP2022523819A (ja) 2022-04-26
IL286048B1 (en) 2024-11-01
CN120484046A (zh) 2025-08-15
US20230233582A1 (en) 2023-07-27
US11559534B2 (en) 2023-01-24
KR102879575B1 (ko) 2025-11-03
CN114026106B (zh) 2025-01-21

Similar Documents

Publication Publication Date Title
BR112021017377A2 (pt) Pró-fármacos de abiraterona
MX2023002478A (es) Profarmacos de abiraterona.
ECSP22055515A (es) Compuestos y métodos para la degradación dirigida del receptor de andrógenos
BR112018070361A2 (pt) redução da carga tumoral através da administração de antagonistas do ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1
CO2019010355A2 (es) Arn terapéutico
JOP20190244A1 (ar) تركيبة علاجية لسرطان البروستاتا
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
PH12017501576A1 (en) Riluzole prodrugs and their use
MX2019005465A (es) Metodo de tratamiento de un tumor inmunoterapeutico.
MX2018016193A (es) Métodos para el tratamiento del cáncer de ovario.
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
MX2015016277A (es) Tratamiento de canceres utilizando moduladores de la isoforma pi3 cinasa.
PE20151750A1 (es) Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico
CL2015002455A1 (es) Terapia de combinación para el tratamiento de la neoplasia.
PH12017500974B1 (en) Prodrugs of phenolic trpv1 agonists
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
UY37800A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
MX2022008175A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
BR112017022281A2 (pt) métodos para tratar câncer
UY39368A (es) Composiciones para modular el empalme
MX2022006280A (es) Uso de la composición para potenciar el efecto anticancerígeno que contiene el inhibidor de err? como principio activo.
MX2019013071A (es) Metodo de tratamiento inmunoterapeutico de un tumor.
ECSP22043592A (es) Inhibidores de egfr alost?ricos y m?todos de uso de los mismos
PH12020550151A1 (en) Methods of treating prostate cancer
PH12021550033A1 (en) Tumor reduction formulations and methods of use thereof